Last reviewed · How we verify
NCT04184973
Efficacy and Safety of the CG-100 Intraluminal Bypass Device
NA trial testing CG-100 intraluminal bypass device in Rectal Cancer in 250 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Colospan Ltd. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 250 |
| Start date | 23 June 2020 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 14 locations across Italy, United States, Israel |
Drugs / interventions tested
- CG-100 intraluminal bypass device
- Stoma
Conditions studied
- Rectal Cancer — all drugs for Rectal Cancer →
- Rectal Tumor — all drugs for Rectal Tumor →
- Rectal/Anal — all drugs for Rectal/Anal →
Sponsor
Colospan Ltd.
Who can join
Adults 22 to 70, any sex, with Rectal Cancer or Rectal Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04184973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Cancer
Currently open trials in the same condition.
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT07501845 — Registry Maastro Applicator · recruiting
- NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
- NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting
Other Colospan Ltd. trials
Trials by the same sponsor.
- NCT05632744 — Evaluation of CG-100 Intraluminal Bypass Device · NA · unknown
- NCT03423485 — Safety and Performance of the CG-100 in Patients Undergoing Colorectal Surgery. · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04184973 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Colospan Ltd.
- Last refreshed: 23 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04184973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing